Loading...
Docoh

PLx Pharma (PLXP)

PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

Company profile

Ticker
PLXP
Exchange
Website
CEO
Natasha Giordano
Employees
Incorporated
Location
Fiscal year end
Former names
Dipexium Pharmaceuticals, Inc., Dipexium Pharmaceuticals, LLC
SEC CIK
Subsidiaries
PLx Opco Inc. ...

PLXP stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 May 22
8 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 52.5M 52.5M 52.5M 52.5M 52.5M 52.5M
Cash burn (monthly) 5.63M 2.66M 6.07M 6.43M 5.63M 3.73M
Cash used (since last report) 24.18M 11.42M 26.04M 27.62M 24.18M 16M
Cash remaining 28.32M 41.08M 26.46M 24.88M 28.32M 36.5M
Runway (months of cash) 5.0 15.4 4.4 3.9 5.0 9.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Mar 22 O'Connor Rita M Common Stock Buy Acquire P No No 3.6546 3,700 13.52K 26,670
15 Mar 22 O'Connor Rita M Common Stock Buy Acquire P No No 3.66 10,000 36.6K 22,970
15 Mar 22 Giordano Natasha Common Stock Buy Acquire P No No 3.6529 4,100 14.98K 5,186
22 Feb 22 Balkema Gary S. Stock Option Common Stock Grant Acquire A No No 4.99 20,000 99.8K 20,000
22 Feb 22 Calhoun Kirk K Stock Option Common Stock Grant Acquire A No No 4.99 20,000 99.8K 20,000
22 Feb 22 Casale Robert Stock Option Common Stock Grant Acquire A No No 4.99 20,000 99.8K 20,000
51.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 52 59 -11.9%
Opened positions 10 12 -16.7%
Closed positions 17 17
Increased positions 11 22 -50.0%
Reduced positions 19 12 +58.3%
13F shares Current Prev Q Change
Total value 133.67M 119.72M +11.7%
Total shares 14.21M 14.94M -4.9%
Total puts 156.2K 179.2K -12.8%
Total calls 149.5K 384.3K -61.1%
Total put/call ratio 1.0 0.5 +124.1%
Largest owners Shares Value Change
White Rock Capital Management 2.81M $22.52M 0.0%
Level One Partners 2.77M $22.21M 0.0%
MSD Partners 1.88M $7.58M 0.0%
Park West Asset Management 1.47M $5.95M 0.0%
Vanguard 1.1M $4.45M -3.7%
MS Morgan Stanley 854.74K $3.45M -0.4%
GW&K Investment Management 428.17K $1.73M -1.1%
BLK Blackrock 406.98K $1.64M -0.4%
Two Sigma Advisers 393.5K $1.59M -15.8%
Two Sigma Investments 338.83K $1.37M -20.3%
Largest transactions Shares Bought/sold Change
Friess Associates 0 -278.07K EXIT
Millennium Management 0 -143.46K EXIT
D. E. Shaw & Co. 111.63K +111.63K NEW
First Republic Investment Management 179.23K -104.29K -36.8%
Shay Capital 88.62K +88.62K NEW
Two Sigma Investments 338.83K -86.31K -20.3%
Two Sigma Advisers 393.5K -73.7K -15.8%
Raymond James & Associates 0 -66.56K EXIT
Cubist Systematic Strategies 12.27K -53.34K -81.3%
MBL Wealth 52K +52K NEW

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: batch, bottle, broader, capacity, category, count, Dipexium, discover, expanding, extend, flow, frozen, grocery, lining, list, longer, notwithstanding, NSAID, optimization, percentage, preclinical, proportionally, screening, seek, store, Topic, variety, warehouse
Removed: account, accredited, affordable, agreement, allocate, annually, annum, approach, arising, arrangement, authority, bank, banking, book, borrowed, calculating, charge, Codification, commencement, compounded, computation, context, continuing, Corporation, deficit, Deposit, depreciable, dividend, employee, enacted, enactment, examination, exposure, face, feature, February, federally, fee, final, floating, foreign, franchise, fulfill, fully, gain, general, greater, housing, identified, inception, initially, institution, insured, intraperiod, investing, investment, January, July, knowledge, largest, liquid, liquidation, making, mitigate, mitigated, monthly, NDA, occurred, October, original, originally, ownership, partially, performed, placement, preference, presence, prime, qualified, qualitative, realized, reborrowed, recovered, relevant, removing, Rent, represent, requirement, requiring, resulting, review, Security, separate, settled, Silicon, simplify, simplifying, step, sublease, subsequently, supplemental, sustained, symbol, tax, taxable, temporary, thereunder, TM, unit, unpaid, Valley, York

Patents

Utility
PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME
2 Jun 22
Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system.
Utility
PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME
6 Jan 22
Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system.
Utility
PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
28 Sep 20
Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts.
Utility
pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
15 Jul 20
Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts.
Utility
PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
11 May 20
Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts.